# Novartis India Ltd (NOVARTIND)
> Exchange: NSE | Sector: Pharma | ISIN: INE234A01025

## Price
Current Price: ₹1365.3
Day Change: +1.39%
52W High: ₹1275
52W Low: ₹950
Market Cap: ₹2,917 Cr

## Valuation
P/E: 29.96
P/B: 3.76
EPS: ₹39.43
Book Value: ₹313.93
Dividend Yield: 0%

## Returns
1Y Return: 36.34%

## Profitability
ROE: 0%
ROCE: 12.82%
Debt/Equity: 0.01
Revenue Growth: -7.6%
Profit Growth: -36.8%
EBITDA Margin: 26.15%
Operating Margin: 25.47%

## About
Novartis India Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Novartis India Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement: Corrigendum To The Notice Of Postal Ballot Issued On April 16, 2026, For The Appointment Of Ms. Gowree Gokhale (DIN: 09351661) As An Independent Director.
- BSE Filing: Announcement under Regulation 30 (LODR)-Newspaper Publication

## Access
Current tier: anonymous
More history: Register free to see 1 more year.

## Data Freshness
Quote Updated: 2026-05-24T20:00:13.396Z
Price History Updated: 2026-05-25T05:31:29.043Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:31:29.043Z
Quant Updated: 2026-05-25T05:31:29.043Z
Sentiment Updated: 2026-05-25T05:31:29.043Z
Financials Status: current
Financials Updated: 2026-05-18T15:31:17.547Z
Financials Last Attempt: 2026-05-18T15:31:17.547Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (FY25)
Revenue: ₹356.26 Cr
Operating Profit: ₹94.17 Cr (OPM 26.43%)
Net Profit: ₹100.9 Cr
Tax: ₹29.52 Cr

## Annual P&L History
FY25: Rev ₹356.26Cr | PAT ₹100.9Cr | OPM 26.43%
FY24: Rev ₹334.04Cr | PAT ₹85.19Cr | OPM 19.54%
FY23: Rev ₹369.11Cr | PAT ₹103.36Cr | OPM 18.76%

## Balance Sheet (FY25)
Total Assets: ₹947.81 Cr
Total Liabilities: ₹162.85 Cr
Borrowings: ₹5.06 Cr
Cash: ₹52.07 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Shilpa Shashank Joshi, CFO & Whole-Time Director
- Falin Ishwarlal Majmudar, Whole–Time Director & Head External Supply Operations
- Chandni Bhupendra Maru, Company Secretary & Compliance Officer
- Vasant  Narasimhan M.D., Chief Executive Officer of Novartis

---
Source: rupiya.io/stocks/novartind
Disclaimer: For research and education only. Not investment advice.